ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models

Jadith Ziegler, Richard Pody, Patricia Coutinho de Souza, Blake Evans, Debra Saunders, Nataliya Smith, Samantha Mallory, Charity Njoku, Yunzhou Dong, Hong Chen, Jiali Dong, Megan Lerner, Osamah Mian, Sai Tummala, James Battiste, Kar-Ming Fung, Jonathan D. Wren, and Rheal A. Towner

Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma (J.Z., R.P., P.C.d.S., B.E., D.S., N.S., S.M., C.N., J.D., O.M., R.A.T.); Comparative Medicine, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma (S.T.); Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma (J.D.W.); Vascular Biology Program, Boston Children’s Hospital and Harvard Medical School, Karp Family Research Laboratories, Boston, Massachusetts (Y.D., H.C.); Department of Pathology, Oklahoma City, Oklahoma (J.Z., K.-M.F., R.A.T.); Department of Biochemistry and Molecular Biology, Oklahoma City, Oklahoma (J.D.W.); Department of Surgery Research Laboratory, Oklahoma City, Oklahoma (M.L.); The Stephenson Cancer Center, Oklahoma City, Oklahoma (J.B., K.-M.F., R.A.T.); The University of Oklahoma Children’s Hospital, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma (S.M.)

Corresponding Author: Rheal A. Towner, PhD, Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104 (rheal-towner@omrf.org).

Abstract
Background. Despite current therapies, glioblastoma is a devastating cancer, and validation of effective biomarkers for it will enable better diagnosis and therapeutic intervention for this disease. We recently discovered a new biomarker for high-grade gliomas, ELTD1 (epidermal growth factor, latrophilin, and 7 transmembrane domain-containing protein 1 on chromosome 1) via bioinformatics, and validated that ELTD1 protein levels are significantly higher in human and rodent gliomas. The focus of this study was to assess the effect on tumor growth of an antibody against ELTD1 in orthotopic, GL261, and G55 xenograft glioma models.

Methods. The effect of anti-ELTD1 antibody therapy was assessed by animal survival, MRI measured tumor volumes, MR angiography, MR perfusion imaging, and immunohistochemistry (IHC) characterization of microvessel density in mouse glioma models. Comparative treatments included anti–vascular endothelial growth factor (VEGF) and anti–c-Met antibody therapies, compared with untreated controls.

Results. Tumor volume and survival data in this study show that antibodies against ELTD1 inhibit glioma growth just as effectively or even more so compared with other therapeutic targets studied, including anti-VEGF antibody therapy. Untreated GL261 or G55 tumors were found to have significantly higher ELTD1 levels (IHC) compared with contralateral normal brain. The anti-angiogenic effect of ELTD1 antibody therapy was observed in assessment of microvessel density, as well as from MR angiography and perfusion measurements, which indicated that anti-ELTD1 antibody therapy significantly decreased vascularization compared with untreated controls.

Conclusions. Either as a single therapy or in conjunction with other therapeutic approaches, anti-ELTD1 antibodies could be a valuable new clinical anti-angiogenic therapeutic for high-grade gliomas.
Ziegler et al. ELTD1, a new anti-angiogenic target for gliomas

High-grade gliomas (World Health Organization grades III/IV) are the most common primary brain tumors in adults, and their malignant nature ranks them fourth in incidence of cancer death.1–4 Approximately 15,000 patients die of glioblastomas in the US annually.1–4 Malignant brain tumors kill ~140,000 people worldwide per year.5 Standard treatment for glioblastoma, which typically involves surgical resection followed by a combination of radiation and chemotherapy with temozolomide, has not improved overall survival (median survival remains 15–18 mo; 5-y survival rates are <10%).24 Prognosis is even poorer for recurrent disease, with response rates for cytotoxic chemotherapy typically in the range of 5%–10%, and a 6-month progression-free survival rate of <15%.8,9 One therapeutic strategy being actively pursued for multiple cancers is targeting angiogenesis, because without the ability to vascularize, a tumor cannot grow in size.

Angiogenesis is greatly upregulated in high-grade gliomas compared with low-grade gliomas20 and is an essential process that provides excess nutrients to developing tumors even at very early stages.11 Assessing angiogenesis is one of the most important criteria for grading tumors in patients.12 In addition to cytotoxic chemotherapy, bevacizumab (Avastin), an anti–vascular endothelial growth factor (VEGF) antibody therapeutic, is used to inhibit angiogenesis as a treatment for recurrent glioblastoma but has not significantly improved clinical outcome.7,10

Antibody development is a well-established technology, with the rate-limiting step in developing antibody-based or biological therapeutics being identification of target proteins to be inhibited. Molecular markers have increasingly been used to assess and manage adult malignant gliomas.5,13–17 Dozens of proteomics-based approaches have sought to find proteins that are unique to gliomas11 but have been severely limited by issues of sample size, ability to detect low abundance proteins, and reproducibility. Many of these studies have generated hundreds and even thousands of putative candidates, yet have not been able to follow them up with subsequent validation and characterization. Alternatively, a bioinformatics approach called global microarray meta-analysis (GAMMA) can be used to interpret empirical patterns from high-throughput data mining of transcriptional expression databases (>75,000 human microarray experiments) by using reported associations within the peer-reviewed literature (>24 million papers) to identify and prioritize uncharacterized proteins for their putative involvement in diseases.18 Whether phenotype or disease relevance for a gene is known or not, a gene can be analyzed indirectly via its highly correlated transcriptional partners.19,20 To identify novel genes associated with gliomas, we can search for all genes that are highly correlated with genes that are already known to be associated with gliomas in the peer-reviewed literature. Using the Human Proteome Reference Database21 and other experimental sources on protein subcellular localizations, a list of predicted glioma-associated proteins can be screened for those that are likely to be expressed on the plasma membrane. Our initial motivation was to identify novel glioma biomarkers, in the hopes that they would be of value for clinical diagnostics, prognostics, or therapeutics. We have validated 6 novel biomarkers specific to gliomas that were identified via the GAMMA bioinformatics approach.22,23 The first of these validated biomarkers was epidermal growth factor, latrophilin, and 7 transmembrane domain-containing protein 1 on chromosome 1 (ELTD1), which we found to be highly enriched in the angiogenic regions of gliomas.22

To our knowledge, this was the first time that surface biomarkers of gliomas were identified by purely computational means.23 ELTD1 has been reported as an endothelial marker in microvasculature.24 In our previous study, ELTD1 was significantly higher (P = .03) in high-grade gliomas (50 patients) compared with low-grade gliomas (21 patients), and this marker compared well with traditional immunohistochemical (IHC) markers used to identify high-grade glioma tissue including VEGF, glucose transporter 1, carbonic anhydrase 9, and hypoxia-inducible factor–1α.22 ELTD1 gene expression was correlated with tumor grade, survival across grades, and an increase in the mesenchymal subtype.22 In a rat F98 glioma model, co-localization images stained for ELTD1 and cluster of differentiation (CD)31 indicated that most of the ELTD1 detected by fluorescence confocal imaging was associated with endothelial cells. Specificity of the ELTD1 probe seems to be in areas associated with neovascularization.22

In this study, we investigated the potential of ELTD1 as an anticancer target via the use of an anti-ELTD1 antibody as a potential therapy in orthotopic mouse GL261 and human G55 xenograft glioma preclinical models. Morphological MRI was used to calculate tumor volumes. Other comparative anticancer therapies included anti-VEGF and/or anti–c-Met antibodies. In addition to tumor volumes, percent animal survival was assessed, as well as IHC evaluation of ELTD1 and CD34 levels. CD34 IHC was used to calculate microvessel densities (MVDs) as a measure of angiogenesis.

Methods

Glioma Models

Two-month-old male C57BL6/J mice or Hsd:Athymic Nude-Foxn1nu mice (Harlan) were intracerebrally implanted with either mouse GL261 (10⁴) or human G55 (10⁵) glioma cells, respectively, as previously done.24–26

Treatments

GL261 tumor-bearing mice (n = 4–7 per group) were treated with either anti-ELTD1 (ELT, N-20, goat polyclonal [sc-46951, Santa Cruz Tech]; 2 mg/kg in 100 µL saline every 3 days for up to tumor maximum), anti-VEGF (mouse monoclonal antibody; 1.5–2.0 mg/kg in 100 µL saline every 3 days for up to tumor maximum [Genentech]), or anti–c-Met antibodies [c-Met, B-2, mouse monoclonal [sc-8057, Santa CruzTech]; 1 mg/kg in 100 µL saline every 3 days for up to tumor maximum]. Untreated mice served as controls for statistical comparison. G55 tumor-bearing mice (n = 5–7/group) were treated with either anti-ELTD1 (same as GL261 model) or anti-VEGF (bevacizumab; Avastin, Genentech), or nonspecific mouse immunoglobulin (IgG) as antibody control (Alpha Diagnostics), or were untreated controls.
Treatments were started when tumors reached 10–20 mm³ in volume. All antibody treatments were administered via a tail vein catheter. All animal studies were approved by the Oklahoma Medical Research Foundation Institutional Animal Care and Use Committee. Animal percent survivals were obtained, with the proviso that all mice were euthanized when tumor volumes reached ≥150 mm³.

MRI

MRI experiments were performed on a Bruker BioSpec 7.0 Tesla/30-cm horizontal-bore magnet imaging system. Animals were immobilized by using 1.5%–2.5% isoflurane and 0.8 L/min O₂ and placed in a 72-mm quadrature volume coil for signal transmission, and a surface mouse-head coil was used for signal reception. T₂-weighted imaging was acquired as previously done by our group.²²,²⁴–²⁶ Tumor volumes were calculated from 3D MRI slices rendered MRI datasets, using Amira v5.6.0 (FEI).

MR Angiography

MR angiography (MRA) was used to obtain macrovascular images (tumor blood vessels >50 μm in diameter) in the GL261 model as previously described.²⁴ Briefly, MRA data were acquired within a volume-of-interest of 1.28 x 1 x 0.64 cm³, at an angle of 16 degrees relative to the horizontal plane, and a flip angle of 90 degrees, for a total acquisition time of 25 min.²⁴ Tumor blood volumes were segmented from 3D MR angiograms and quantified using Mathematica.²³ Datasets were reconstructed to provide a pixel resolution of 50 x 78 x 100 μm³.²⁴ For analysis, a region of interest (ROI) encompassing blood vessels in the tumor area was selected and used to provide absolute tumor blood volumes.²⁴

Perfusion Imaging

In order to assess microvascular alterations associated with tumor capillaries, the perfusion imaging method, arterial spin labeling, was used as previously described.²⁵,²⁶ Perfusion maps were obtained on a single axial slice of the brain located on the point of the rostro-caudal axis where the tumor had the largest cross section.²⁵,²⁶ The imaging geometry was a 3.5 x 3.5 mm² slice, of 1.5 mm in thickness, with a single shot echo-planar encoding over a 64 x 64 matrix. An echo time of 20 ms and a repetition time of 18 s were used. To obtain contrast, the flow alternating inversion recovery scheme was used, where inversion recovery images were acquired using selective and nonselective slices. For each type of inversion, 8 images were acquired with inversion times evenly spaced at 20–2820 ms. For perfusion data, the recovery curves obtained from each pixel for nonselective or selective inversion images were numerically fitted to derive pixelwise T₁ and T₂* values, respectively, and longitudinal recovery rates were then used to calculate the cerebral blood flow, CBF (mL/(100 g·min)), from: CBF = A[(1/T₁*)−(1/T₁)].²⁷ The partition coefficient, λ, was scaled by the value of 0.9 mL/g.²⁸ To calculate differences in relative (r)CBF values, tumor rCBF values were obtained at late tumor stages (days 18–26 following i.c. implantation of GL261 cells, or after tumor detection for G55 cells, for untreated mice, and days 20–31 [after GL261 implantation or G55 tumor detection] for treated mice) and early tumor stages (days 10–13 following GL261 cell implantation or G55 tumor detection) and were normalized to rCBF values in the contralateral brain region of corresponding animals.

Histology and Immunohistochemistry

All mice were euthanized after the last MRI examination. Perfusion fixation (10% neutral buffered formalin administered via a tail vein injection) was used on anesthetized (isoflurane) mice, and whole brain of each animal was removed, further preserved in 10% neutral buffered formalin, and processed routinely. Paraffin-embedded tissues were sectioned at 5 μm, mounted on SuperFrost Plus glass slides (Fisher Scientific), stained with hematoxylin and eosin, and examined by light microscopy. Iron Staining Kit (Ventana Medical Systems) was used to stain for hemorrhaging. IHC was done to establish ELTD1 levels by staining tissue samples with anti-ELTD1 antibody (rabbit anti-ELT, 10 μg/mL; #ab150489, Abcam). For ELTD1 IHC, sections were incubated in an antigen retrieval solution (citrate buffer, pH 6; Vector Laboratories) for 20 min in a rice steamer, followed by a 20-min cooldown in deionized water. ELTD1 IHCs were analyzed using a Positive Pixel Count algorithm with the Aperio ImageScope viewer. Only areas containing tumor tissue were analyzed for IHC expression. Areas without tumor tissue and areas with necrosis or significant artifacts (e.g., tissue folding) were deselected and excluded from analysis. The number of positive pixels was divided by the total number of pixels (negative and positive) in the analyzed area. To characterize MVD and tumor cell invasion, respectively, in both untreated and treated groups, IHC for anti-CD34 antibody (rabbit anti-CD34, 10 μg/mL; #ab81289, Abcam) was performed using an automated immunostainer (Bond-III, Leica). Sections were incubated in an antigen retrieval solution, as described above for ELTD1 IHC. Three ROIs with the highest number of blood vessels (200x magnification) were identified in each case. The MVD measurements were captured digitally for each selected ROI and calculated using the Aperio ScanScope Image Analysis System.²⁹

Western Blot

Tissue and cell lysates were prepared in radioimmunoprecipitation assay buffer, mixed with loading buffer, heated, and loaded (12.5 μg/well) within a Mini-PROTEAN TGX Precast gradient gel 4%–15% (Bio-Rad Laboratories). The ELTD band was visualized using ELT (N-20; #sc-46951) antibody as a primary, and a secondary donkey anti-goat (#sc-2020) IgG–horseradish peroxidase.

Statistical Analysis

Statistical analyses were performed using ANOVA with a post Tukey’s multiple comparison test for evaluating differences in tumor volumes between untreated and treated...
groups. Data were represented as mean ± SD, and P-values <.05, <.01, and <.001 were considered statistically significant.

**Results**

We established initially whether GL261 or G55 tumors expressed high levels of ELTD1. ELTD1 IHC levels in untreated GL261 or G55 gliomas, compared with contralateral normal brain tissue, are depicted in Fig. 1. The levels of ELTD1 were significantly higher in tumor regions (P < .0001, GL261; P < .01, G55) compared with contralateral brain tissue (Fig. 1E and F, respectively). ELTD1 was found in high levels also in tumor and human vascular endothelial cells, as well as GL261 and G55 glioma cells (Fig. 1G). Due to the high levels of ELTD1 expression and its known role in angiogenesis, we then set out to

**Fig. 1** ELTD1 is highly expressed in GL261 and G55 gliomas. Representative IHC for ELTD1 in untreated GL261 (A) and G55 (B) tumors; 20 × magnification. Representative IHC for ELTD1 in the contralateral normal brain region of GL261 (C) and G55 (D) tumor-bearing mice; 20 × magnification. ELTD1 staining (horseradish peroxidase) positivity (N positive/N total) in untreated (UT) GL261 (E) or G55 (F) tumors (n = 5 for each) compared with contralateral normal brain regions (n = 7 for each) (G) Western blot showing ELTD1 levels in primary astrocytes (ASTR), GL261 and G55 glioma cells, and tumor endothelial cells (TEC) or human umbilical vein endothelial cells (HUVEC). There was a significant increase in ELTD1 levels in GL261 (P < .0001) or G55 (P < .01) gliomas compared with normal contralateral brain tissue in each model. Magnification bar = 100 µm.
determine whether interfering with ELTD1 function via anti-ELTD1 antibody therapy would increase overall survival and decrease tumor volumes compared with untreated tumors.

We found that percent survival of GL261 and G55 glioma-bearing mice treated with anti-ELTD1 antibodies was significantly higher ($P < .01$ for both) compared with untreated and/or IgG-treated tumors, as depicted in Fig. 2A and G,

**Fig. 2** Anti-ELTD1 antibody therapy increases animal survival and decreases tumor volumes in GL261 and G55 gliomas. Animal survival curves for GL261 (A) and G55 (G) glioma-bearing mice either untreated (UT) ($n = 5–9$) or treated with IgG ($n = 7$) or antibodies against either ELTD1 (ELTD) ($n = 7–9$), c-Met ($n = 5$), or VEGF ($n = 4–5$). There was a significant increase in survival for all treated groups ($P < .01$ for all treatment groups), compared with untreated mice. Tumor volumes (mm$^3$), measured from multiple MR image slices either GL261 (B) or G55 (H) glioma mice, UT mice, or mice treated with IgG or antibodies against VEGF, ELTD1 (ELTD), or c-Met. There was a significant decrease in tumor volumes for all treated groups ($P < .05$ [GL261] or $P < .0001$ [G55] for VEGF, $P < .001$ [GL261] or $P < .001$ [G55] for ELTD, and $P < .01$ [GL261] for c-Met) compared with UT animals. Representative T2-weighted MRIs from GL261 (C–F) (21 days following GL261 cell implantation) or G55 (I–L) glioma-bearing mice either untreated (C or I), or treated with IgG (J) or antibodies against VEGF (D or K), ELTD1 (E or L), or c-Met (F). Tumor volumes obtained from T2-weighted image slices (M) that were 3D rendered (N).
respectively. Other antibody therapies, including anti-mouse anti-VEGF ($P < .01$, GL261; $P < .001$, G55) or anti-c-Met ($P < .01$ for GL261) antibodies also significantly increased animal survival compared with untreated GL261 (Fig. 2A) or IgG-treated or untreated G55 (Fig. 2G) gliomas. Tumor volumes at 21 days following intracerebral implantation of GL261 or 21 days after tumor detection for G55 cells were found to be significantly lower in anti-ELTD1 antibody-treated mice ($P < .001$ for both) compared with untreated controls or IgG-treated mice ($P < .05$, G55) (Fig. 2B and H, respectively). Likewise, anti-VEGF and anti-c-Met antibody treatments also had significantly decreased tumor volumes ($P < .05$ for anti-VEGF in GL261, $P < .0001$ for anti-VEGF in G55, and $P < .01$ for anti-c-Met in GL261) compared with untreated animals (Fig. 2B and H, respectively). Many of the untreated GL261 or untreated and IgG-treated G55 glioma-bearing mice were required to be euthanized, as tumor volumes reached $\sim 150$ mm$^3$ at the 21-day timepoint (following cell implantation for GL261 or after tumor detection for G55).

Representative MRIs of GL261 tumor-bearing mice from all treatment groups are shown in Fig. 2C–F, whereas those from G55 tumor-bearing mice are shown in Fig. 2I–L. A representative 3D rendered tumor volume of the tumor from Fig. 2M is shown in Fig. 2N. We also noticed in the anti-VEGF–treated animals that several of the MRIs indicated hemorrhaging in the tumors (eg, Fig. 2D and K) compared with anti-ELTD1–treated (Fig. 2E and L) tumors. Histology (iron stain) was obtained to verify the hemorrhaging observed in the MRIs, particularly for the anti-VEGF–treated GL261 or G55 tumors. Figure 3 shows representative iron stained tumor tissues from each treatment group. Very little to no hemorrhaging is seen for the IgG-treated (Fig. 3A and D) or anti-ELTD1–treated (Fig. 3B and E) tumors compared with high areas of hemorrhaging seen for the anti-VEGF–treated tumors (Fig. 3C and Fi and Fii).

MVA assessment was done to establish whether anti-ELTD1 antibody therapy would affect tumor-associated vasculature. Representative lectin IHC images for each treatment group are shown in Fig. 4A–D. Microvessel density assessment for all treatment groups is shown in Fig. 4E, indicating that anti-ELTD1 antibody therapy significantly decreased MVD compared with untreated GL261 glioma-bearing mice ($P < .01$). MVD was also significantly decreased for either anti-c-Met ($P < .05$) or anti-VEGF ($P < .0001$) therapies compared with untreated tumors. Anti-ELTD1 therapy was not found to be significantly lower than either anti-c-Met or anti-VEGF groups.

MRA was performed and analyzed for the GL261 model to assess whether anti-ELTD1 therapy would be effective against tumor-associated macrovasculature (>$50$ µm in diameter). Representative morphological MRIs and MRA overlays of the brain regions from comparative untreated and anti-ELTD1 GL261 glioma-bearing mice are shown in Fig. 5A–D. Figure 5E illustrates the quantitative assessment of the tumor blood volumes (mm$^3$) that were calculated from MRAs obtained within brain regions of GL261 glioma-bearing mice that were either untreated (mean of 21 days following GL261 cell implantation) or treated with anti-ELTD1 antibody at day 21 following GL261 cell implantation or at maximum tumor volumes, or treated with anti-VEGF at maximum tumor volumes. There was a significant decrease in total tumor blood volume in the anti-ELTD1
Ziegler et al. ELTD1, a new anti-angiogenic target for gliomas

Figure 4 Anti-ELTD1 antibody treatment decreases MVD. Representative IHC slides for CD34 obtained from GL261 (A–D) or G55 (F–H) gliomas that were either untreated (UT) (A [GL261], F–H [G55]) or treated with mouse anti-VEGF (B [GL261], G [G55]), anti-ELTD1 (C [GL261], H [G55]), or anti–c-Met (D [GL261]) antibodies. Histogram of MVD for all treatment groups (UT, n = 5; black bar or anti-VEGF, n = 4–5; dark gray bar), anti-ELTD1 (n = 5–6; white bar), or anti–c-Met (n = 5; light gray bar) in GL261 (E) or G55 (J) tumors. Note darker brown staining around vessels in UT (both GL261 [A] and G55 [F]) or IgG-treated (G55 [G]) CD34 IHC samples. Significant decreases in MVD were found for only the anti-ELTD1 treatment group compared with UT mice (P < .01 [GL261] or P < .05 [G55]). Anti-VEGF (P < .01 [GL261] or P < .05 [G55]) or anti–c-Met (P < .05 [GL261]) therapies also had significantly decreased MVD compared with UT mice. 20 × magnification for all slides. Magnification bar = 100 µm.

Discussion

This study focuses on the observation that antibodies to ELTD1 inhibit the growth of mouse GL261 and human G55 xenograft gliomas. It was observed that ELTD1 protein expression was found to be significantly higher in GL261 and G55 glioma tissue (P < .01) compared with contralateral normal brain tissue (Fig. 1). Regarding treatment response,
our data show that multiple intravenous injections of anti-ELTD1 antibodies lead to a significant decrease in tumor volumes and an increase in animal survival (Fig. 2). Given a lifespan factor of 37.5 between mice and humans, the extra 7–10 days in survival time gained by anti-ELTD1 therapy would translate into approximately a year for humans. Furthermore, the magnitude of the effect from this unoptimized polyclonal antibody is similar to, if not slightly better than, that achieved by a mouse monoclonal anti-VEGF antibody (humanized version of bevacizumab [Avastin]) in GL261 tumors or Avastin in G55 gliomas. Another group recently found that microRNA-139-5p acts as a tumor suppressor in glioblastomas by targeting ELTD1 and regulating the cell cycle.

In particular, anti-ELTD1 therapy was found to significantly decrease MVD compared with untreated tumors (Fig. 4) and...
was just as effective as anti-VEGF therapy. Our GL261 angiography results indicated that anti-ELTD1 antibody therapy was effective in reducing tumor macrovasculature (>50 µm in diameter), whereas anti-VEGF antibody therapy had no significant effect (Fig. 5). Regarding the use of perfusion imaging to assess microvascularity, anti-ELTD1 antibody therapy was found to be quite effective in reducing tumor-related microvascularity, and this therapy seemed to be more effective than anti-VEGF therapy, particularly in the G55 model (Fig. 6). It seems that anti-VEGF therapy, unlike anti-ELTD1, seems to not be effective against macrovascularity and mainly alters microvascularity in gliomas. With the use of MRA and dynamic contrast enhanced MRI by other investigators, it was determined that bevacizumab/paclitaxel combined therapy did not block the blood supply to an MCF-7 (Michigan Cancer Foundation 7) breast tumor xenograft in severe combined immunodeficient mice, which diminished any microvascular changes targeted by the anti-VEGF antibody therapy.36 This finding is consistent with the modest survival benefits of adding bevacizumab to current treatment regimens for some types of cancers,27 such as gliomas.27,10

We also found that the anti-VEGF therapy was found to increase hemorrhaging in the G55 tumors compared with other treatments (Fig. 3). It is well known that bevacizumab (Avastin) causes intracranial hemorrhaging as a potential serious adverse event in >10% of glioblastoma multiforme patients with this treatment34–36 and that anti-VEGF therapy has been associated with reports of hemorrhaging in other tissues.37,38 Perhaps anti-ELTD1 antibody therapy may be more beneficial, as we did not observe this adverse event in the histological or MR images in the GL261 or G55 glioma model data compiled in this study. Although, since some of the reports for anti-VEGF therapy indicated a 10% frequency,37 a greater sample size for anti-ELTD1 therapy may be required to confirm our finding.

Our bioinformatics analysis suggests that ELTD1 is induced in angioblasts, regions of neovascularization, and not in normal tissue,52 further indicating that this

---

**Fig. 6** Anti-ELTD1 antibody therapy alters tumor-associated vascularity as measured by MRI perfusion. Representative T2-weighted MRIs from GL261 (A, C) or G55 (F, H, J) glioma-bearing mice either untreated (UT) (A or F) or ELTD1 (ELTD) (C or H) or VEGF (J) antibody treated. Representative MR perfusion maps from either GL261 (B, D) or G55 (G, I, K) glioma-bearing mice, either UT (B or G) or ELTD (D or I) or VEGF (K) antibody treated. Normalized (against muscle tissue) tumor rCBF differences at late to early time periods for tumor growth measured from MR perfusion images obtained from GL261 (E) or G55 (L) glioma-bearing mice from either UT mice or mice treated with IgG or antibodies against ELTD or VEGF. There was a significant decrease in tumor rCBF for the ELTD-treated mice (P<.0001 [GL261] or P<.01 [G55]), as well as with VEGF-treated mice (P<.001 [GL261]) compared with UT animals. ELTD-treated mice also had a significant decrease in rCBF in G55 gliomas (P<.05) compared with IgG-treated tumors. VEGF-treated mice did not have a significant difference (eg, note decreased perfusion for VEGF [panel K]) compared with IgG-treated mice.
molecular target may be ideal for anti-angiogenic therapy. Reports by Masiero et al.,39 Favara et al.,40 and Serban et al.41 also support our data that ELTD1 is a key regulator of angiogenesis. Unfortunately, the current published data on ELTD1 function, its ligand, and structure are rather limited at this time.41 MRA and MR perfusion imaging indicated that ELTD1 was able to decrease the tumor blood vasculature (blood vessels >50 μm in diameter) (see Fig. 5) and differences in tumor rCBF values (see Fig. 6), respectively. Anti-ELTD1 antibody therapy seems to affect both macro- and microvasculature associated with tumor growth, whereas in this study anti-VEGF antibody therapy seems to affect only tumor microvasculature. The MVD data seem to also support this finding, as MVD takes into consideration both macro- and microvasculature measurements. Perhaps anti-ELTD1 therapy can be used as a potentially safer alternate anti-angiogenic therapy clinically. Anti-ELTD1 antibody therapy may also be considered to be used in combination with anti-c-Met therapy in future studies. Our data, in addition to other independent reports recently published,39,40,42,43 suggest that ELTD1 is a promising therapeutic candidate for inhibition of angiogenesis in gliomas and quite possibly in other tumors as well.

**Funding**

Funding was provided by the Oklahoma Medical Research Foundation (to R.A.T.), the Chapman Foundation (to J.D.W.), and the National Institute of General Medical Sciences of the National Institutes of Health (NIH NIGMS) grant no. 5P20GM103636-02 (to J.D.W.). An Institutional Development Award (IDeA) from the NIH NIGMS, grant no. 5P20GM103639 (to K.-M.F.) for the use of the Histology and Immunohistochemistry Core at the Stephenson Cancer Center, which provided immunohistochemistry and image analysis services, also assisted with funding.

**Conflict of interest statement.** None of the authors have any conflict of interest.

**References**


Downloaded from https://academic.oup.com/neuro-oncology/article-abstract/19/2/175/2631677 by guest on 14 April 2019


